Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$100.66 USD

100.66
1,338,879

-0.01 (-0.01%)

Updated Aug 12, 2024 04:00 PM ET

After-Market: $100.64 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (200 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016

by Sweta Killa

The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy Amid Mixed Investor Sentiments

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy LOB, MAR, CAH, FN and WING.

Moumi Mondal headshot

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

by Moumi Mondal

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

Wingstop and Marriott Vacations Worldwide have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Wingstop and Marriott Vacations Worldwide are part of the Zacks Bull and Bear of the Day article.

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

by Zacks Equity Research

Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Tirthankar Chakraborty headshot

3 Top Dividend Aristocrats to Buy Ahead of 2024

by Tirthankar Chakraborty

Some of the dividend aristocrats, such as Cardinal Health (CAH), Atmos Energy (ATO) and NextEra Energy (NEE), have a better-quality business and strong underlying fundamentals.

Should Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for OMFL

Maharathi Basu headshot

5 Broker-Favorite Stocks to Keep an Eye on as 2024 Approaches

by Maharathi Basu

We believe that stocks like American Airlines (AAL), ABM Industries (ABM), Cardinal Health (CAH), Cleveland-Cliffs (CLF) and Cencora (COR) should be on an investor's watchlist.

Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Cardinal Health (CAH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

by Zacks Equity Research

Here is how Cardinal Health (CAH) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cardinal (CAH) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What's in Store for Cooper Companies (COO) in Q4 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

McKesson (MCK) Announces Availability of FDA-Cleared Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.

Zacks.com featured highlights Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx

by Zacks Equity Research

Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx have been highlighted in this Screen of The Week article.

Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.

Sweta Killa headshot

5 Dividend Stocks Having Strong Growth Potential

by Sweta Killa

Cboe Global (CBOE), Cardinal Health (CAH), Assurant (AIZ), Installed Building Products (IBP) and FedEx (FDX) have a strong dividend growth potential.

Maharathi Basu headshot

5 Broker-Friendly Stocks to Keep an Eye on Amid Volatility

by Maharathi Basu

We believe that stocks like Brinker International (EAT), Cardinal Health (CAH), The Andersons (ANDE), Avnet (AVT) and Group 1 Automotive (GPI) should be on an investor's watchlist.

Derek Lewis headshot

This Combination of 3 Stocks Provides Monthly Income

by Derek Lewis

Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?

3 Reasons to Retain Inspire Medical (INSP) Stock for Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome

by Zacks Equity Research

Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.